Page 1

SILENCE THERAPEUTICS Silence Therapeutics Provides mRNAI GOLD ™ Platform and Pipeline Updates at 2021 R & D Day 10/21/2021 • • Silence Therapeutics Provides mRNAI GOLD ™ Platform and Pipeline Updates at 2021 R & D Day Announces plans to initiate a Phase 1 study in polycythaemia vera ( PV ) with SLN124 , the third indication being assessed using endogenous hepcidin modulation SLN360 single - ascending dose study on - track for topline data in Q1'22 - independent review committee recommends extending follow - up period to assess potential longer duration of action • Advancing mRNAI GOLDTM platform programs - poised to deliver 2-3 INDS per year from 2023 21 October 2021 , LONDON and NEW YORK -- Silence Therapeutics plc ( AIM : SLN and Nasdaq : SLN ) , a leader in the discovery , development and delivery of novel short interfering ribonucleic acid ( siRNA ) therapeutics for the treatment of diseases with significant unmet medical need , announces it is hosting its R & D Day in New York City today . During the event , Silence plans to showcase its proprietary mRNAI GOLD ™ platform and current clinical programs , including SLN360 for cardiovascular disease due to high lipoprotein ( a ) , or Lp ( a ) , and SLN124 for thalassemia and myelodysplastic syndrome ( MDS ) as well as a newly added program in polycythemia vera ( PV ) . Silence will also provide an update on its growing discovery pipeline and plans to deliver 2-3 INDs per year from 2023 . Mark Rothera , President and Chief Executive Officer of Silence Therapeutics , said : " The vision at Silence has always been to build an exquisite platform that would enable the development of longer - lasting precision medicines to transform patients ' lives . We are pleased to report strong progress across both our proprietary and partnered 1